Medical/Pharmaceuticals
Neurophth Expands Its Global Gene Therapy Leadership Team with the Appointment of Dr. Zhengbin Li as Head of Commercial
WUHAN, China and SAN DIEGO, Aug. 19, 2021 /PRNewswire/ -- Neurophth Biotechnology Ltd., a fully-integrated genomic medicines company committed to the development of AAV-delivered gene therapies for the treatment of ocular diseases, today announced the recent appointment of Dr. Zhengbin (Luke) Li ...
2021-08-19 22:00
2270
Daewoong Pharmaceutical and Hanall Biopharma Invest $1M USD in Alloplex Biotherapeutics
SEOUL, South Korea, Aug. 19, 2021 /PRNewswire/ -- Daewoong Pharmaceutical and
Hanall Biopharma ofSouth Korea are expanding their global open collaboration
initiative by investing in Alloplex Biotherapeutics, an emergingBoston-based
biotechnology company.
2021-08-19 21:00
2986
Speclipse attracts $7.7M in investments with its laser spectroscopic and artificial intelligence medical diagnosis technology
SEOUL, South Korea, Aug. 19, 2021 /PRNewswire/ -- Speclipse, a startup specializing in laser spectroscopic and AI-based medical diagnosis technologies and a member ofBorn2Global Centre, recently attracted USD 7.7 million in investments for an accumulated investment total ofUSD 13 million. ...
2021-08-19 20:30
1996
PharmAbcine Announces Submission of PCT for an Anti-ANG2 Antibody for the Treatment of Ocular Diseases
DAEJEON, South Korea, Aug. 19, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, today announced it submitted a Patent Cooperation Treaty (PCT), an international patent application, for ...
2021-08-19 20:00
1772
I-Mab Announces Establishment of Environmental, Social and Governance Committee
* I-Mab received highest first-time ESG rating among China-based biotech companies from MSCI * New majority independent ESG committee to set overall ESG strategies for the Company * Women account for two-thirds of the total workforce and over 30% of I-Mab's Board of Directors * Committed ...
2021-08-19 19:00
4811
Senhwa's Silmitasertib Receives US FDA Fast Track Designation for the Treatment of Recurrent Sonic Hedgehog Driven Medulloblastoma
TAIPEI and SAN DIEGO, Aug. 18, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focused on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, today announced that the US Food and Drug Administration (FDA) has granted Fast Tr...
2021-08-19 10:57
2285
MicroConstants to Join BioAgilytix Family
Highly complementary transaction strengthens BioAgilytix's ability to support bioanalytical services across all major therapeutics in development; adds LC/MS/MS capabilities; and expands team of seasoned scientists DURHAM, N.C., Aug. 18, 2021 /PRNewswire/ -- BioAgilytix Labs, LLC (BioAgilytix),...
2021-08-19 02:30
2114
Henlius reports half-year (H1) 2021 results, outlines remarkable growth in commercialization and needs-driven innovation
SHANGHAI, Aug. 18, 2021 /PRNewswire/ -- Henlius (2696.HK) announced Half-Year (H1) results endedJune 30th, 2021, sharing the company's recent noteworthy progress and achievements. As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, affordable and innov...
2021-08-18 21:35
4446
Holmusk signs agreements with UTHealth and The Harris Center
NEW YORK, Aug. 17, 2021 /PRNewswire/ -- Holmusk, a leading global data science and health technology company building the world's largest Real-World Evidence (RWE) platform for behavioral health, has signed data license agreements with TheUniversity of Texas Health Science Center at Houston (UTHe...
2021-08-17 21:00
2107
I-Mab to Provide Business and Corporate Updates and Report Financial Results for the Six Months Ended June 30, 2021 on August 31, 2021
SHANGHAI and GAITHERSBURG, Md., Aug. 17, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced it will provide business and corporate updates and repo...
2021-08-17 20:00
3346
PharmAbcine to Participate in Biotechgate Digital Partnering
DAEJEON, South Korea, Aug. 17, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will participate in Biotechgate Digital Partnering taking place virtuall...
2021-08-17 20:00
1769
Angel Pharmaceuticals Announces IND Acceptance for Clinical Trial of ITK Inhibitor CPI-818 in China
JIAXING, China and BURLINGAME, Calif., Aug. 16, 2021 /PRNewswire/ -- Angel Pharmaceuticals Ltd. ("Angel Pharma") today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted its IND application for the initiation of a Phase 1/...
2021-08-17 05:00
2100
First Edition of World Conference on Early Detection of Cancer Set to Start in November in Hainan, China
GUANGZHOU and HAIKOU, China, Aug. 16, 2021 /PRNewswire/ -- Early detection and diagnosis of cancer is an essential enabler of curative treatment and an effective solution to boost the survival rates of cancer patients worldwide. In an effort to lead the way in innovative research and strategies f...
2021-08-16 22:13
2395
Myungsung C&M launches a new MARPE
BUCHEON, South Korea, Aug. 16, 2021 /PRNewswire/ -- Myungsung C&M, a Korean
orthodontic product manufacturer, has recently released its new product, which
is A+ Expander as MARPE that Myungsung C&M introduces.
2021-08-16 21:00
2130
111, Inc. Deepens Partnership with Bayer Healthcare
SHANGHAI, Aug. 16, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced the expansion of its existing partnership with Baye...
2021-08-16 20:00
7351
Gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell Therapies Targeting Claudin 18.2 in Solid Tumors
SUZHOU and SHANGHAI, China, and PALO ALTO, Calif., Aug. 16, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today ...
2021-08-16 20:00
3189
Senhwa Completes Enrollment of a Phase 2 Investigator Initiated Trial of Silmitasertib as Novel Oral Drug for COVID-19
TAIPEI and SAN DIEGO, Aug. 16, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focused on human efficacy and innovation of first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, today announced that its novel oral drug, Silmita...
2021-08-16 15:29
2169
GeneQuantum announces a key leadership appointment
SUZHOU, China, Aug. 15, 2021 /PRNewswire/ -- GeneQuantum Healthcare, an industry leading biopharmacetucial company dedicated to next generation bioconjugate drugs through innovative intelligent ligase-dependent conjugation (iLDC) technology platform, announced a key appointment to further strengt...
2021-08-16 10:00
1736
InnoCare Announces First Subject Dosed in Clinical Trial of ICP-332
BEIJING, Aug. 15, 2021 /PRNewswire/ -- InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on drug innovation for cancer and autoimmune diseases, announced today the first subject dosed in clinical trial of novel TYK2 (Tyrosine Kinase 2) inhibitor ICP-332 inChina. InnoCare disc...
2021-08-16 09:32
8320
InxMed's IN10018 Receives U.S. FDA Fast Track Designation for the Treatment of Platinum-resistant Ovarian Cancer
NANJING, China, Aug. 15, 2021 /PRNewswire/ -- InxMed (Nanjing) Co., Ltd. ("InxMed" or "Company"), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced today the U.S. Food and Drug Administration (FDA) has granted Fas...
2021-08-16 09:31
1959
Week's Top Stories
Most Reposted
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 308 media titles]
2026-05-19 18:10
Two-day Global Prosperity Summit 2026 officially opens
[Picked up by 308 media titles]
2026-05-19 23:59
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 303 media titles]
2026-05-21 22:13
Hyundai Motor Group to Pioneer Hong Kong's Hydrogen Economy, Accelerating Asia-Pacific Expansion
[Picked up by 290 media titles]
2026-05-18 15:30
Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
[Picked up by 280 media titles]
2026-05-20 09:15Most Read
PT Telkom Indonesia (Persero) Tbk 2025 Annual Report on Form 20-F
2026-05-16 00:26
7319
Eyes that photosynthesise: NUS scientists plant a cure for dry eye disease
2026-05-16 11:14
5337
Lepro Introduces STV1, a TV Backlight That Combines Screen Sync, AI Lighting, and Easier Setup
2026-05-16 00:00
5039
NYSE Content Update: Exchange Turns 234 Ahead of U.S. Semiquincentennial
2026-05-18 21:29
5010
NYSE Content Update: Armada Raises $230 Million, Boosts Valuation to $2 Billion
2026-05-19 21:02
4914
